Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Goodwill & Intangibles (2016 - 2025)

ImmunityBio (IBRX) has disclosed Goodwill & Intangibles for 12 consecutive years, with $14.0 million as the latest value for Q4 2025.

  • Quarterly Goodwill & Intangibles fell 12.43% to $14.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.0 million through Dec 2025, down 12.43% year-over-year, with the annual reading at $14.0 million for FY2025, 12.43% down from the prior year.
  • Goodwill & Intangibles for Q4 2025 was $14.0 million at ImmunityBio, down from $14.5 million in the prior quarter.
  • The five-year high for Goodwill & Intangibles was $22.3 million in Q1 2022, with the low at $1.4 million in Q4 2021.
  • Average Goodwill & Intangibles over 5 years is $14.4 million, with a median of $16.3 million recorded in 2024.
  • The sharpest move saw Goodwill & Intangibles surged 1454.17% in 2022, then dropped 15.45% in 2024.
  • Over 5 years, Goodwill & Intangibles stood at $1.4 million in 2021, then soared by 1308.66% to $20.0 million in 2022, then fell by 14.55% to $17.1 million in 2023, then fell by 6.79% to $15.9 million in 2024, then fell by 12.43% to $14.0 million in 2025.
  • According to Business Quant data, Goodwill & Intangibles over the past three periods came in at $14.0 million, $14.5 million, and $15.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.